Goals in Focus: CBT for Motivational Negative Symptoms of Psychosis
Launched by UNIVERSITY OF HAMBURG-EPPENDORF · Feb 22, 2022
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
The "Goals in Focus" trial is looking at a new therapy designed to help people with psychosis, particularly those experiencing motivational negative symptoms, which can make it hard to feel motivated or enjoy life. This study is currently recruiting participants who are diagnosed with a schizophrenia spectrum disorder and have moderate to severe motivational symptoms. To be eligible, participants need to be able to speak German, commit to weekly 50-minute therapy sessions, and be motivated to reduce their symptoms.
If you or someone you know qualifies and decides to participate, you can expect to take part in a structured therapy program that aims to improve motivation and overall quality of life. The study will help researchers understand how effective this new approach is, paving the way for larger studies in the future. It's important to note that individuals with severe risks to themselves or others, or those currently receiving other specific therapies for these symptoms, will not be eligible for this trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ICD-10 diagnosis of a schizophrenia spectrum disorder (confirmed by the Structured Clinical Interview for DSM V Clinical Version
- • at least moderate motivational negative symptoms (i.e., scores ≥ 3 (moderate) in two items or ≥ 4 (moderately severe) in one item of the 'motivation and pleasure factor' of the Brief Negative Symptom Scale (BNSS)
- • sufficient skills in German language to participate in psychological therapy
- • capable to engage in weekly therapy sessions of 50-minutes
- • prioritize the reduction of negative symptoms as their current goal for treatment
- • capable to give informed consent to participate in the trial
- Exclusion Criteria:
- • being at immediate and serious risk to self or others
- • co-morbid diagnosis of alcohol or substance use disorder
- • intake of Benzodiazepines for \>2 days per week
- • receiving any other psychological treatment aiming to reduce motivational negative symptoms
About University Of Hamburg Eppendorf
The University of Hamburg-Eppendorf (UKE) is a prominent academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and education. As a leading clinical trial sponsor, UKE integrates cutting-edge scientific inquiry with clinical practice, fostering a multidisciplinary approach to health challenges. The institution is dedicated to conducting high-quality clinical trials that adhere to rigorous ethical standards, promoting patient safety and contributing valuable insights to the medical community. With a focus on collaboration and excellence, UKE aims to translate research findings into effective therapeutic strategies, ultimately enhancing patient outcomes and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
Patients applied
Trial Officials
Tania M Lincoln, Prof. Dr.
Principal Investigator
Universität Hamburg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials